ARK Invest Led by Cathie Wood Joins Cellares’ $277 Million Series D Funding Round
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), has announced a new strategic investment from ARK Invest as part of its Series D financing round. The investment adds $20 million to the round, bringing the total Series D funding to $277 million and reinforcing growing institutional confidence in next-generation cell therapy manufacturing infrastructure.
The financing round brings together a strong consortium of global investors, including BlackRock, Eclipse Ventures, T. Rowe Price, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors, underscoring the increasing convergence of biotechnology, automation, and large-scale industrial manufacturing.
ARK Invest Highlights Manufacturing Bottleneck in Cell Therapy
Commenting on the investment, Cathie Wood, Founder, CEO, and CIO of ARK Invest, emphasized that while scientific progress in cell therapy has been strong, the central challenge remains manufacturing scalability and cost efficiency.
According to Wood, the science behind cell therapy is already well established, but the industry now faces a critical bottleneck: producing personalized, living therapies at a scale that meets global patient demand. She noted that current manufacturing systems remain highly complex, expensive, and dependent on manual processes that limit throughput.
ARK Invest views Cellares as addressing this structural challenge by integrating robotics, software, and biotechnology into a unified manufacturing platform. This convergence, she explained, transforms cell therapy production from a highly customized, labor-intensive process into an automated, industrial-scale system capable of consistent and scalable output.
Wood added that infrastructure platforms like Cellares are likely to become foundational to the future of medicine, particularly as next-generation therapies move from experimental treatments into mainstream clinical use.
Reimagining Cell Therapy Manufacturing Through Automation
Ovid Amadi, PhD, Multiomics Portfolio Manager and Director of Research at ARK Invest, further elaborated on the technical and structural reasons behind the investment. He described cell therapy manufacturing as one of the most difficult challenges in modern medicine, primarily due to the complexity of producing living, patient-specific treatments under strict Good Manufacturing Practice (GMP) conditions.
Traditional manufacturing methods, he noted, are poorly suited to this type of production. Manual workflows, fragmented vendor ecosystems, and limited automation create inefficiencies that restrict scalability and increase cost.
Cellares has attempted to address this challenge by developing a vertically integrated manufacturing model known as the IDMO framework. This model consolidates multiple layers of the biomanufacturing ecosystem—including tools development, automation systems, and contract manufacturing services—into a single, unified platform.
According to ARK Invest’s analysis, this integration effectively displaces the traditional separation between equipment providers, automation vendors, and contract development and manufacturing organizations (CDMOs). Instead, it creates a streamlined system designed specifically for cell therapy production at scale.
Dr. Amadi also highlighted that Cellares’ platform has undergone validation across multiple processes and has already demonstrated commercial traction through major supply agreements. These include partnerships with Bristol Myers Squibb and Cabaletta Bio, both of which provide real-world evidence of the platform’s commercial readiness.
He further noted a key milestone in April, when the first patients were successfully infused with cell therapy products manufactured using Cellares’ automated system. This event, according to ARK Invest, represented a critical proof point that the company’s technical capabilities had translated into real clinical applications.
Leadership Perspective: Scaling Cell Therapy for Global Access
Fabian Gerlinghaus, Co-Founder and CEO of Cellares, emphasized that the recent achievements validate years of development in automated cell therapy manufacturing. He stated that the successful production and delivery of clinical-grade therapies using the company’s Cell Shuttle platform demonstrates that industrial-scale manufacturing of living therapies is no longer theoretical but operationally achievable.
Gerlinghaus highlighted that the key question facing the industry has shifted. It is no longer whether automation can support cell therapy manufacturing, but whether such systems can operate reliably at commercial scale while significantly reducing production costs.
He explained that addressing this challenge is essential to expanding patient access. Cell therapies, particularly CAR-T treatments, have shown strong clinical efficacy but remain limited by manufacturing complexity, long production timelines, and high costs.
The company’s long-term vision is to resolve these constraints by building a global network of automated manufacturing facilities capable of delivering consistent, high-quality cell therapies at scale.
Validation Through Clinical Manufacturing Milestones
The new Series D investment follows a series of important operational and clinical milestones for Cellares. In April, the company successfully manufactured and delivered the first two Good Manufacturing Practice (GMP) doses of rese-cel, an investigational CAR T cell therapy developed by Cabaletta Bio. These doses were produced using the Cell Shuttle® platform and met all required release specifications before being administered to patients on schedule.
This achievement marked a significant validation of the platform’s ability to support real-world clinical manufacturing requirements, not just laboratory-scale or pilot production.
In parallel, Cabaletta Bio entered into a 10-year commercial supply agreement with Cellares, signaling long-term confidence in the company’s ability to support future production needs as therapies advance toward broader commercialization.
Additionally, Cellares previously announced a major $380 million global manufacturing agreement with Bristol Myers Squibb. This agreement reserves large-scale manufacturing capacity across the United States, Europe, and Japan for BMS’s cell therapy pipeline, further strengthening Cellares’ position as a global manufacturing partner for leading pharmaceutical companies.
Expanding Global Manufacturing Infrastructure
Cellares currently operates IDMO Smart Factories in South San Francisco, California, and Bridgewater, New Jersey. These facilities serve as the foundation of the company’s automated manufacturing network and are designed to support standardized, scalable production of cell therapies.
In addition to its U.S. operations, the company is expanding internationally with facilities under development in Leiden, the Netherlands, and Kashiwa City, Japan. This global footprint is intended to ensure consistent manufacturing standards across regions while enabling pharmaceutical partners to access localized production capacity.
The long-term vision is to establish a fully integrated global manufacturing network capable of supporting hundreds of thousands of patient treatments annually beginning in 2027.
The IDMO Model and the Future of Biomanufacturing
At the core of Cellares’ strategy is the IDMO model, which represents a shift away from traditional contract manufacturing toward fully integrated, automated production systems. Unlike conventional CDMOs that rely heavily on manual processes and fragmented supply chains, the IDMO approach combines process development, automation engineering, and manufacturing operations into a single unified platform.
This model is designed to reduce variability, improve production speed, and significantly lower the cost per therapy dose. It also aims to solve one of the most persistent challenges in cell therapy: scaling personalized treatments without compromising quality or regulatory compliance.
As cell therapies continue to expand into new indications, including oncology, autoimmune diseases, and rare genetic disorders, the need for scalable manufacturing infrastructure is expected to grow substantially.
The $20 million investment from ARK Invest into Cellares’ Series D round underscores rising investor confidence in automated biomanufacturing as a critical enabler of next-generation medicine.
Backed by a strong syndicate of global institutional investors and supported by early clinical and commercial validation, Cellares is positioning itself at the forefront of a structural transformation in cell therapy production. With its IDMO Smart Factory network expanding globally and key pharmaceutical partnerships already in place, the company is aiming to redefine how living therapies are manufactured, scaled, and delivered to patients worldwide.
About The ARK Venture Fund
The ARK Venture Fund (ARKVX) is an actively managed, closed-end interval fund that seeks long-term growth of capital by investing in both private and public equities of companies at the frontier of disruptive innovation. The fund is designed to democratize access to venture capital by giving investors exposure to high-growth private companies alongside public holdings across the full company lifecycle, from early-stage through public market transition. For more information, visit ark-funds.com.
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand.
Cellares’ fully automated platforms — Cell Shuttle® for end-to-end cell therapy manufacturing and Cell Q™ for automated in-process and release quality control — are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry.
The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes.
Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial — marking the platform’s transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications.
Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide.
